Helsinn urges SCOTUS to define drugs’ on-sale bar in pivotal case against Teva
Helsinn filed a petition asking the high court to review a May 2017 decision by the U.S. Federal Circuit Court of Appeals that invalidated its patents on Aloxi at the request of Teva Pharmaceutical Industries Ltd based on the “on-sale bar,” a provision of patent law that states an invention... Continue reading